Nanjing Vazyme Biotech Toekomstige groei
Future criteriumcontroles 5/6
Nanjing Vazyme Biotech is forecast to grow earnings and revenue by 76.3% and 23.8% per annum respectively. EPS is expected to grow by 75.8% per annum. Return on equity is forecast to be 7.7% in 3 years.
Belangrijke informatie
76.3%
Groei van de winst
75.8%
Groei van de winst per aandeel
Biotechs winstgroei | 44.8% |
Inkomstengroei | 23.8% |
Toekomstig rendement op eigen vermogen | 7.7% |
Dekking van analisten | Low |
Laatst bijgewerkt | 19 Sep 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 2,416 | 365 | N/A | 475 | 1 |
12/31/2025 | 1,970 | 297 | N/A | 397 | 1 |
12/31/2024 | 1,572 | 104 | N/A | 436 | 1 |
9/30/2024 | 1,403 | 24 | 7 | 72 | N/A |
6/30/2024 | 1,364 | 26 | -67 | 34 | N/A |
3/31/2024 | 1,285 | -15 | 12 | 181 | N/A |
12/31/2023 | 1,286 | -71 | -80 | 153 | N/A |
9/30/2023 | 2,133 | -232 | 152 | 589 | N/A |
6/30/2023 | 2,520 | -101 | 126 | 649 | N/A |
3/31/2023 | 2,896 | 112 | -128 | 553 | N/A |
12/31/2022 | 3,569 | 594 | -228 | 735 | N/A |
9/30/2022 | 2,885 | 878 | -367 | 445 | N/A |
6/30/2022 | 2,663 | 900 | -291 | 440 | N/A |
3/31/2022 | 2,302 | 773 | -123 | 453 | N/A |
12/31/2021 | 1,869 | 678 | 355 | 617 | N/A |
9/30/2021 | 1,715 | 767 | 315 | 583 | N/A |
12/31/2020 | 1,564 | 822 | 651 | 804 | N/A |
12/31/2019 | 268 | 26 | -5 | 15 | N/A |
12/31/2018 | 171 | 1 | -36 | -4 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 688105's forecast earnings growth (76.3% per year) is above the savings rate (2.9%).
Winst versus markt: 688105's earnings (76.3% per year) are forecast to grow faster than the CN market (25.8% per year).
Hoge groeiwinsten: 688105's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: 688105's revenue (23.8% per year) is forecast to grow faster than the CN market (14% per year).
Hoge groei-inkomsten: 688105's revenue (23.8% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 688105's Return on Equity is forecast to be low in 3 years time (7.7%).